RBC Life Sciences (RBCL) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 31, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'RBC LIFE SCIENCES, INC.	'
Entity Central Index Key	'0000830052	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	2,212,350

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$4,331,173	$3,896,087
Accounts receivable, net of allowance for doubtful accounts of $30,137 and $29,361, respectively	1,008,474	877,275
Inventories	4,958,089	5,084,900
Deferred income taxes	450,460	462,088
Prepaid expenses and other current assets	1,445,939	833,458
Total current assets	12,194,135	11,153,808
Property and equipment, net	4,059,804	4,488,374
Goodwill, net	2,280,874	2,298,020
Intangible assets, net	39,468	43,936
Other assets	265,375	30,283
Total assets	18,839,656	18,014,421
Current liabilities:	'	'
Accounts payable, trade	1,584,585	1,495,194
Accrued liabilities	1,292,636	1,111,131
Current maturities of long-term obligations	208,410	196,678
Deferred revenue	4,315,265	3,230,506
Total current liabilities	7,400,896	6,033,509
Long-term obligations, less current maturities	1,191,014	1,348,821
Deferred income taxes	1,018,974	1,116,593
Shareholders' equity:	'	'
Common stock, $0.001 par value; 50,000,000 shares authorized; 22,228,834 shares issued and outstanding at June 30, 2012 and December 31, 2011	2,212	2,223
Additional paid-in capital	13,705,163	13,708,736
Accumulated deficit	-4,614,327	-4,314,278
Accumulated other comprehensive income	135,724	118,817
Total shareholders' equity	9,228,772	9,515,498
Total liabilities and shareholders' equity	$18,839,656	$18,014,421

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Allowance for doubtful accounts	$25,000	$27,417
Shareholders' equity:	'	'
Common stock par value (in dollars per share)	$0.00	$0.00
Common stock shares authorized	50,000,000	50,000,000
Common stock shares issued	2,212,350	2,222,834
Common stock shares outstanding	2,212,350	2,222,834

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Condensed Consolidated Statements of Operations Quarter [Abstract]	'	'	'	'
Net sales	$6,639,767	$6,713,068	$19,025,267	$19,330,438
Cost of sales	3,603,644	3,641,838	10,045,641	9,675,295
Gross profit	3,036,123	3,071,230	8,979,626	9,655,143
Operating expenses:	'	'	'	'
General and administrative	2,301,086	2,701,483	6,799,783	7,381,314
Distributor commissions	746,805	777,602	2,112,672	2,436,765
Depreciation and amortization	126,752	128,025	380,123	377,733
Gain (Loss) on Casualty	0	0	0	-443,064
Total operating expenses	3,174,643	3,607,110	9,292,578	9,752,748
Operating profit (loss)	-138,520	-535,880	-312,952	-97,605
Interest expense	27,436	31,149	85,156	96,085
Earnings (loss) before income taxes	-165,956	-567,029	-398,108	-193,690
Provision (benefit) for income taxes	-22,985	-238,025	-100,157	-111,562
Net earnings (loss)	-142,971	-329,004	-297,951	-82,128
Other comprehensive income (loss):	'	'	'	'
Foreign currency translation adjustment	-11,077	-13,293	16,907	-20,255
Comprehensive income (loss)	($154,048)	($342,297)	($281,044)	($102,383)
Net earnings (loss) per share:	'	'	'	'
Basic	($0.06)	($0.15)	($0.13)	($0.04)
Diluted	($0.06)	($0.15)	($0.13)	($0.04)
Weighted average common shares outstanding:	'	'	'	'
Basic	2,217,044	2,222,883	2,220,916	2,222,883
Diluted	2,217,044	2,222,883	2,220,916	2,222,883

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net earnings (loss)	($297,951)	($82,128)
Adjustment for non-cash items:	'	'
Depreciation and amortization	441,593	428,710
Stock-based compensation	14,289	28,092
Deferred income taxes and other	-86,349	147,354
Casualty gain	0	-443,064
Change in operating assets and liabilities:	'	'
Accounts receivable	-131,190	-300,045
Inventories	120,317	892,329
Prepaid expenses and other current assets	-616,625	-310,789
Other assets	-235,650	-4,385
Accounts payable and accrued liabilities	281,655	-457,432
Deferred revenue	1,085,001	-479,984
Net cash provided by (used in) operating activities	575,090	-581,342
Cash flows from investing activities:	'	'
Purchase of property and equipment	-11,292	-805,131
Insurance proceeds	0	625,247
Net cash used in investing activities	-11,292	-179,884
Cash flows from financing activities:	'	'
Payments of long-term obligations	-146,075	-135,060
Purchase of common stock	-17,824	0
Net cash used in financing activities	-163,899	-135,060
Effect of exchange rate changes on cash flows	35,187	-45,414
Net increase (decrease) in cash and cash equivalents	435,086	-941,700
Cash and cash equivalents, beginning of period	3,896,087	3,858,544
Cash and cash equivalents, end of period	$4,331,173	$2,916,844

Unaudited_Condensed_Consolidat

Unaudited Condensed Consolidated Financial Statements	9 Months Ended
	Sep. 30, 2013
Restatement of Prior Year Income [Abstract]	'
Unaudited Condensed Consolidated Financial Statements	'
	Unaudited Condensed Consolidated Financial Statements:
	The accompanying unaudited condensed consolidated financial statements, including the notes thereto, of RBC Life Sciences, Inc. (sometimes hereinafter referred to collectively as “we”, “our”, "us" “RBC” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Certain information and disclosures that are normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to these rules and regulations.  These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 (the “2012 Form 10-K”), previously filed with the Securities and Exchange Commission.
	In the opinion of management, all adjustments (consisting solely of normal recurring accruals) considered necessary for a fair presentation of the Company's results for the interim periods have been included.  The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates.  The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year.  Subsequent events were evaluated through the issuance date of the condensed consolidated financial statements.
	Stock Splits
	On August 9, 2013, the Company completed a 1-for-500 reverse stock split (the "Reverse Split"), whereby each 500 shares of the Company's issued and outstanding shares of common stock, $0.001 par value (the "Common Stock"), was converted into one whole share of new common stock (the "New Common Stock"). No fractional shares were issued in connection with the Reverse Split. In lieu of issuing fractional shares to shareholders in connection with the Reverse Split, the Company will pay $0.1691 per share to shareholders.
	Immediately following the Reverse Split, the Company completed a 50-for-1 forward stock split (the "Forward Split" and together with the Reverse Split, the "Stock Splits") whereby each share of New Common Stock was converted into 50 shares of Common Stock.
	The Common Stock began trading at the split-adjusted price on August 12, 2013. All share numbers and per share amounts presented reflect the Stock Splits. Amounts recorded as common stock and additional paid in capital within the Shareholders' Equity section of the Condensed Consolidated Balance Sheets have been restated to reflect the impact of the Stock Splits.
	New Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income ("ASU 2013-02"), which provides guidance to update the presentation of reclassifications from comprehensive income to net income in consolidated financial statements. Under this new guidance, an entity is required to provide information about the amounts reclassified out of accumulated other comprehensive income either by the respective line items of net income or by cross-reference to other required disclosures. The new guidance does not change the requirements for reporting net income or other comprehensive income in financial statements. This guidance is effective for fiscal years beginning after December 15, 2012. We adopted this guidance effective January 1, 2013. The adoption of this guidance did not have a material effect on our consolidated financial statements.

Nature_of_Operations_and_Organ

Nature of Operations and Organization	9 Months Ended
	Sep. 30, 2013
Nature of Operations and Organization [Abstract]	'
Nature of Operations and Organization	'
	Nature of Operations and Organization:
	The Company is principally engaged in the marketing of nutritional supplements and personal care products (collectively “Nutritional Products”) through subsidiaries in the United States, Canada, Taiwan and Hong Kong.  This product line is marketed under the “RBC LifeTM” brand name.  In these markets, the Company markets its products through a network of distributors that are referred to as “Associates.”  The Associates are independent contractors who purchase products for personal use, purchase products for resale to retail customers and sponsor other individuals as Associates.  Accordingly, Associates may be product consumers only or they may also seek to derive compensation both from the direct sales of products and from sales generated by sponsored Associates. In certain other markets in Southeast Asia and Australia, the Company sells its products through a not-for-resale ("NFR") program. Individuals who participate in the NFR program function similarly to other Associates in that they can sponsor others and derive compensation from sales generated by individuals they sponsor. However, they may only order products for personal use and may not resell products to retail customers.
	RBC also markets its Nutritional Products in certain international markets through license arrangements.  The licensees are third parties who are granted exclusive rights to distribute RBC products in their respective territories and, for the most part, distribute these products through an independent Associate network in the licensed territory.  Under these arrangements, the independent Associate network in a licensed territory is compensated by the licensee.
	In addition to its Nutritional Products, RBC also markets a line of wound care products (“Medical Products”) under the "MPM MedicalTM" brand name through a U.S. subsidiary.  Medical Products are distributed primarily in the United States to hospitals, nursing homes, clinics and pharmacies through traditional medical/surgical supply dealers, pharmaceutical distributors and our own sales representatives.  Medical Products are used to treat and manage pain associated with wounds in the acute care, long-term care and oncology markets.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2013
Inventories [Abstract]	'
Inventories	'
	Inventories:
	Inventories consist of the following:
		September 30, 2013		December 31, 2012
	Raw materials and bulk products	$	266,580	$	176,872
	Packaging materials	293,085		364,258
	Finished goods	4,398,424		4,543,770
		$	4,958,089	$	5,084,900

Prepaid_Expenses_and_Other_Cur

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2013
Prepaid Expenses [Abstract]	'
Prepaid Expenses and Other Current Assets	'
	Prepaid Expenses and Other Current Assets:
	Prepaid expenses and other current assets consist of the following:
		September 30, 2013		December 31, 2012
	Advance payment to suppliers	$	417,980	$	223,267
	Prepaid income taxes	291,384		303,983
	Advances to Associates	145,108		—
	Certificates of deposit - restricted	82,654		85,357
	Prepaid insurance and other	508,813		220,851
		$	1,445,939	$	833,458
	At September 30, 2013 and December 31, 2012, the Company held certificates of deposit in the amounts of approximately $83,000 and $85,000, respectively, which were pledged to secure surety bonds.
	During the first nine months of 2013, the Company entered into agreements with an Associate to market Nutritional Products in Australia, Hong Kong and other Asian markets. Pursuant to these agreements, the Company made cash advances to this Associate to support marketing activities and fund costs related to the opening of an office in Hong Kong. Also in accordance with the agreements, these advances do not bear interest, and are to be recovered from monthly marketing fees calculated as a percentage of sales that are generated in the Associate's markets.
	On July 30, 2013, the Company was notified by the Associate that he was unable to fulfill certain of his financial obligations under the agreements. The Company deemed this failure to represent a material breach of the agreements. Through July 31, 2013, the Company had advanced funds to this Associate totaling approximately $403,000.
	Because the Associate was unable to fulfill his financial obligations related to the operation of the Hong Kong office, the Company has continued to advance funds in order to keep the Hong Kong office in operation. Through September 30, 2013, net advances under the agreements were $493,000, which represents gross advances of $527,000, less $34,000 in marketing fees earned through that date. Advances made after July 31, 2013 total approximately $115,000. Due to the risk that not all of the advances will be recovered from marketing fees, advances made after July 31, 2013 are fully reserved, and the related expense is included in general and administrative expense during the period.
	Advances outstanding (net of marketing fees earned and reserves for uncollectible advances) as of September 30, 2013 were approximately $381,000. Of this amount, $145,000 represents the portion of the advances that the Company expects to be recovered from marketing fees over the next 12 months and is classified as a prepaid expense. The remaining balance is included in other assets.

Property_and_Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2013
Property and Equipment [Abstract]	'
Property and Equipment	'
	Property and Equipment:
	Property and equipment consists of the following:
		September 30, 2013			December 31, 2012
	Building and improvements	$	3,834,193		$	3,812,692
	Computer software and office equipment	2,440,309			2,444,383
	Warehouse equipment	234,625			234,625
	Automotive equipment	14,717			14,717
		6,523,844			6,506,417
	Less – accumulated depreciation	(3,605,213		)	(3,159,216		)
		2,918,631			3,347,201
	Land	1,141,173			1,141,173
		$	4,059,804		$	4,488,374
	Depreciation expense totaled approximately $145,800 and $144,300 for the quarters ended September 30, 2013 and 2012, respectively, and $437,100 and 424,200 for the nine months ended September 30, 2013 and 2012, respectively.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	9 Months Ended
	Sep. 30, 2013
Goodwill and Other Intangible Assets [Abstract]	'
Goodwill and Other Intangible Assets	'
	Goodwill and Other Intangible Assets:
	The Company measures its goodwill for impairment at the end of each year or in the event of an impairment indicator.  No impairment losses have been recognized as a result of this testing.  Goodwill balances are summarized as follows:
		Gross Carrying Value				Accumulated Amortization
	Balance, December 31, 2012	$	3,435,305			$	(1,137,285	)
	Currency translation adjustment	(33,458		)		16,312
	Balance, September 30, 2013	$	3,401,847			$	(1,120,973	)
	Other intangible assets consist of the following:
				September 30, 2013							December 31, 2012
		Average		Gross				Accumulated			Gross		Accumulated
		Life		Carrying				Amortization			Carrying		Amortization
		(years)		Value							Value
	Copyrights, trademarks and other registrations	19		$	99,100			$	(64,084	)	$	99,100	$	(60,119	)
	Other	19		12,600				(8,148		)	12,600		(7,644		)
				$	111,700			$	(72,232	)	$	111,700	$	(67,763	)
	Amortization expense related to other intangible assets totaled approximately $1,500 for the quarters ended September 30, 2013 and 2012, and $4,500 for the nine months ended September 30, 2013 and 2012.  The aggregate estimated amortization expense for intangible assets remaining as of September 30, 2013 is as follows:
	Remainder of 2013	$	1,488
	2014	5,957
	2015	5,957
	2016	5,957
	2017	5,957
	Thereafter	14,152
		$	39,468

Accrued_Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2013
Accrued Liabilities [Abstract]	'
Accrued Liabilities	'
	Accrued Liabilities:
	Accrued liabilities consist of the following:
		September 30, 2013		December 31, 2012
	Distributor commissions	$	556,508	$	443,707
	Salaries and wages	535,042		499,894
	Sales and property taxes	102,120		69,483
	Medical products sales rebates	73,221		52,611
	Interest	9,038		9,981
	Other	16,707		35,455
		$	1,292,636	$	1,111,131

LongTerm_Obligations

Long-Term Obligations	9 Months Ended
	Sep. 30, 2013
Long Term Obligations And Credit Lines [Abstract]	'
Long-Term Obligations	'
	Long-Term Obligations:
	Long-term obligations consist of the following:
		September 30, 2013			December 31, 2012
	Mortgage note payable bearing interest at 7.75%, payable in monthly installments of $25,797 through April 2019, collateralized by land and building, and personally guaranteed by the Company’s Chairman of the Board of Directors and Chief Executive Officer	$	1,399,424		$	1,545,499
	Less – current maturities	(208,410		)	(196,678		)
		$	1,191,014		$	1,348,821
	The fair value of long-term debt is estimated based on interest rates for the same or similar instruments offered having the same or similar maturities and collateral requirements.  At September 30, 2013, the fair value of fixed-rate long-term debt was approximately $1,518,000, which was $119,000 above the carrying value of approximately $1,399,000.  At December 31, 2012, the fair value of fixed-rate long-term debt was approximately $1,713,000, which was $168,000 above the carrying value of approximately $1,545,000.

ShareBased_Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2013
Share-based Compensation [Abstract]	'
Share-Based Compensation	'
	Share-Based Compensation:
	The Company records compensation expense for all share-based payments based on the estimated grant date fair value.  Share-based compensation expense was approximately $4,800 and $10,400 for the quarters ended September 30, 2013 and 2012, respectively, and $14,300 and $28,100 for the nine months ended September 30, 2013 and 2012, respectively.  Share-based compensation is classified as a general and administrative expense.  There were no material tax benefits related to this expense because virtually all share-based compensation resulted from grants of incentive stock options.
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:
		Quarters Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
		-1		-1		-1
	Weighted average expected life (years)	—		—		—		6
	Risk-free interest rate	—	%	—	%	—	%	0.96	%
	Expected volatility	—	%	—	%	—	%	310.09	%
	Expected dividend yield	—	%	—	%	—	%	—	%
	__________________
	(1) There were no option grants during these periods.
	All share numbers and per share amounts presented reflect the Stock Splits. See Note A for additional information regarding the Stock Splits. A summary of stock option activity for the nine months ended September 30, 2013 is as follows:
		Options		Weighted-Average Exercise Price per Share			Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
	Outstanding on December 31, 2012	86,126		$	4
	Granted	—		—
	Exercised	—		—
	Forfeited/canceled	(15,090	)	2.87
	Outstanding on September 30, 2013	71,036		$	4.19		4.2	$	—
	Exercisable on September 30, 2013	53,060		$	4.44		3.5	$	—
	A summary of the status of the Company's non-vested stock options as of September 30, 2013 and changes during the nine months then ended are presented below:
		Shares		Weighted-Average Grant Date Fair Value per Share
	Non-vested stock options at December 31, 2012	19,976		$	2.94
	Non-vested stock options granted	—		—
	Vested stock options	(2,000	)	2.5
	Forfeited stock options	—		—
	Non-vested stock options at September 30, 2013	17,976		2.98
	As of September 30, 2013, there was approximately $41,200 of total unrecognized compensation cost related to stock option grants

Segments_and_Geographic_Area

Segments and Geographic Area	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Segments and Geographic Area	'
	Segments and Geographic Area:
	The Company's segments are based on the organizational structure that is used by management for making operating and investment decisions and for assessing performance.  Based on this structure, the Company has two operating segments: Nutritional Products and Medical Products.
	The Nutritional Products segment manufactures and distributes a line of over 100 nutritional supplements and personal care products, including herbs, vitamins and minerals, as well as natural skin, hair and body care products.  Nutritional Products are marketed under the "RBC LifeTM" brand name through subsidiaries in the United States, Canada, Taiwan and Hong Kong.  These products are distributed by a network comprised of independent Associates and NFR program participants in certain markets, primarily the United States, Canada and Southeast Asia, and by licensees in other international markets.  For the most part, licensees also market the Nutritional Products in their respective territories through a network of independent Associates.
	The Medical Products segment markets a line of over 40 wound care products under the "MPM MedicalTM" brand name through a subsidiary operating primarily in the United States.  These wound care products are distributed to hospitals, nursing homes, home health care agencies, clinics and pharmacies through a network of medical/surgical supply dealers, pharmaceutical distributors and our own sales representatives.  Medical Products are used to treat and manage pain associated with wounds, in the acute care, long-term care and oncology markets.
	The Company evaluates the performance of its segments primarily based on operating profit.  All intercompany transactions have been eliminated, and intersegment revenues are not significant.  In calculating operating profit for these two segments, administrative expenses incurred that are common to the two segments are allocated on a usage basis.
	Segment information is as follows (U.S. dollars in 000s):
		Nutritional Products			Medical Products			Consolidated
	Quarter Ended September 30, 2013
	Net sales	$	4,999		$	1,640		$	6,640
	Depreciation and amortization	132			15			147
	Operating profit (loss)	(203		)	64			(139		)
	Capital expenditures	—			—			—
	Total assets	15,683			3,157			18,840
	Quarter Ended September 30, 2012
	Net sales	$	5,301		$	1,412		$	6,713
	Depreciation and amortization	127			19			146
	Operating loss	(453		)	(83		)	(536		)
	Capital expenditures	100			—			100
	Total assets	14,901			2,829			17,730
	Nine Months Ended September 30, 2013
	Net sales	$	14,431		$	4,594		$	19,025
	Depreciation and amortization	395			46			442
	Operating profit (loss)	(360		)	47			(313		)
	Capital expenditures	11			—			11
	Total assets	15,683			3,157			18,840
	Nine Months Ended September 30, 2012
	Net sales	$	14,652		$	4,678		$	19,330
	Depreciation and amortization	370			59			429
	Operating profit (loss)	(210		)	112			(98		)
	Capital expenditures	805			—			805
	Total assets	14,901			2,829			17,730
	Financial information summarized geographically is as follows (U.S. dollars in 000s):
		Quarter Ended September 30, 2013						Quarter Ended September 30, 2012
		Net sales			Long-Lived assets			Net sales			Long-Lived assets
	Domestic	$	2,455		$	5,859		$	2,422		$	6,442
	Russia/Eastern Europe	3,078			—			3,333			—
	Canada	374			528			339			521
	Southeast Asia	707			258			566			60
	All others	25			—			54			—
	Totals	$	6,640		$	6,645		$	6,713		$	7,023
		Nine Months Ended September 30, 2013						Nine Months Ended September 30, 2012
		Net sales			Long-Lived assets			Net sales			Long-Lived assets
	Domestic	$	7,129		$	5,859		$	7,969		$	6,442
	Russia/Eastern Europe	8,856			—			8,717			—
	Canada	1,184			528			1,072			521
	Southeast Asia	1,747			258			1,305			60
	All others	110			—			267			—
	Totals	$	19,025		$	6,645		$	19,330		$	7,023
	Significant Customers
	The Company recorded sales of Nutritional Products to Coral Club International, Inc. ("CCI"), a licensee of the Company, in the amounts of $3,078,000 and $3,333,000 during the quarters ended September 30, 2013 and 2012, respectively, and $8,856,000 and $8,717,000 during the nine months ended September 30, 2013 and 2012, respectively.  The President of CCI is a former member of our Board of Directors and beneficially owns approximately 18% of our Common Stock. The Company also recorded sales of Medical Products to a medical/surgical dealer (see Note L for additional information related to this dealer) in the amounts of $672,000 and $612,000 during the quarters ended September 30, 2013 and 2012, respectively, and $1,960,000 and $2,512,000 during the nine months ended September 30, 2013 and 2012, respectively.  In no other case did a customer of the Company account for more than 10% of net sales during the quarters or nine months ended September 30, 2013 and 2012.

Earnings_Loss_Per_Share

Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings (Loss) Per Share	'
	Loss Per Share:
	All share numbers and per share amounts presented reflect the Stock Splits. See Note A for additional information regarding the Stock Splits. Summarized basic and diluted loss per common share was calculated as follows:
		Net Loss			Weighted	Per Share
					Average
					Shares
	Quarter Ended September 30, 2013
	Basic loss per common share	$	(142,971	)	2,217,044	$	(0.06	)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(142,971	)	2,217,044	$	(0.06	)
	Quarter Ended September 30, 2012
	Basic loss per common share	$	(329,004	)	2,222,883	$	(0.15	)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(329,004	)	2,222,883	$	(0.15	)
	Nine Months Ended September 30, 2013
	Basic loss per common share	$	(297,951	)	2,220,916	$	(0.13	)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(297,951	)	2,220,916	$	(0.13	)
	Nine Months Ended September 30, 2012
	Basic loss per common share	$	(82,128	)	2,222,883	$	(0.04	)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(82,128	)	2,222,883	$	(0.04	)
	The average number of stock options that were outstanding, but not included in the computation of diluted loss per common share because their exercise price was greater than the average market price of the common stock, or were otherwise anti-dilutive, was approximately 71,000 and 107,400 for the quarters ended September 30, 2013 and 2012, respectively, and approximately 76,000 and 103,000 for the nine months ended September 30, 2013 and 2012, respectively.

Legal_Proceedings

Legal Proceedings	9 Months Ended
	Sep. 30, 2013
Legal Proceedings [Abstract]	'
Legal Proceedings	'
	Legal Proceedings:
	One medical/surgical dealer accounts for a significant portion of Medical Products sales. This dealer distributes our Medical Products and provides services primarily to nursing homes, and obtains reimbursement for the price of our products from Medicare. This dealer accounted for approximately $1,960,000 and $2,512,000, or 10% and 13% of the Company's sales during the nine months ended September 30, 2013 and 2012, respectively.
	On February 27, 2012, we were notified that this dealer filed a voluntary petition for protection under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Central District of California in Santa Ana, California on February 24, 2012. According to its bankruptcy petition, this dealer filed its petition as the most effective means of stabilizing its finances as it resolves a reimbursement guidelines dispute with Medicare, which the dealer believes is improperly withholding payments. The petition states that this dealer relies on Medicare payments for more than 90% of its revenue and that Medicare has suspended payments to the dealer. In a press release issued by the dealer at the time of the filing, the dealer stated that the Chapter 11 filing will allow it to continue operating without interruption while it resolves its payment dispute with Medicare as expeditiously as possible. In June 2012, we filed a proof of claim in this bankruptcy proceeding for the unpaid amount owing to us. As of September 30, 2013, we had approximately $240,000 in pre-petition accounts receivable that remain owed by this dealer. Since the bankruptcy filing, we have continued to fill this dealer's post-petition orders, with payments received in accordance with our normal terms. On August 23, 2013, the dealer filed its proposed plan of reorganization which, at this time, contemplates paying our pre-petition claim in full; however, the plan has not been confirmed. While we believe the amounts due to us from this dealer will be collected in full, we will continue to monitor these proceedings as they progress in order to appropriately assess and enforce our rights in this matter.
	From time to time, we are a party to claims, litigation or other legal or administrative proceedings that we consider to arise in the ordinary course of our business. No assurances can be given regarding the outcome of these or any other pending proceedings, or the ultimate effect such outcomes may have. However, other than as stated above, we do not believe we are a party to any legal or administrative proceedings which, if determined adversely to us, individually or in the aggregate, would have a material effect on our financial position, results of operations or cash flows.

Unaudited_Condensed_Consolidat1

Unaudited Condensed Consolidated Financial Statements (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
New Accounting Pronouncements	'
	New Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income ("ASU 2013-02"), which provides guidance to update the presentation of reclassifications from comprehensive income to net income in consolidated financial statements. Under this new guidance, an entity is required to provide information about the amounts reclassified out of accumulated other comprehensive income either by the respective line items of net income or by cross-reference to other required disclosures. The new guidance does not change the requirements for reporting net income or other comprehensive income in financial statements. This guidance is effective for fiscal years beginning after December 15, 2012. We adopted this guidance effective January 1, 2013. The adoption of this guidance did not have a material effect on our consolidated financial statements.

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2013
Inventories [Abstract]	'
Schedule of Inventories	'
	Inventories consist of the following:
		September 30, 2013		December 31, 2012
	Raw materials and bulk products	$	266,580	$	176,872
	Packaging materials	293,085		364,258
	Finished goods	4,398,424		4,543,770
		$	4,958,089	$	5,084,900

Prepaid_Expenses_and_Other_Cur1

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Prepaid Expenses [Abstract]	'
Schedule of Prepaid Expenses and Other Current Assets	'
	Prepaid expenses and other current assets consist of the following:
		September 30, 2013		December 31, 2012
	Advance payment to suppliers	$	417,980	$	223,267
	Prepaid income taxes	291,384		303,983
	Advances to Associates	145,108		—
	Certificates of deposit - restricted	82,654		85,357
	Prepaid insurance and other	508,813		220,851
		$	1,445,939	$	833,458

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Property and Equipment [Abstract]	'
Schedule of Property and Equipment	'
	Property and equipment consists of the following:
		September 30, 2013			December 31, 2012
	Building and improvements	$	3,834,193		$	3,812,692
	Computer software and office equipment	2,440,309			2,444,383
	Warehouse equipment	234,625			234,625
	Automotive equipment	14,717			14,717
		6,523,844			6,506,417
	Less – accumulated depreciation	(3,605,213		)	(3,159,216		)
		2,918,631			3,347,201
	Land	1,141,173			1,141,173
		$	4,059,804		$	4,488,374

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Other Intangible Assets [Abstract]	'
Summary of Goodwill Balances	'
	Goodwill balances are summarized as follows:
		Gross Carrying Value				Accumulated Amortization
	Balance, December 31, 2012	$	3,435,305			$	(1,137,285	)
	Currency translation adjustment	(33,458		)		16,312
	Balance, September 30, 2013	$	3,401,847			$	(1,120,973	)
Schedule of Other Intangible Assets	'
	Other intangible assets consist of the following:
				September 30, 2013							December 31, 2012
		Average		Gross				Accumulated			Gross		Accumulated
		Life		Carrying				Amortization			Carrying		Amortization
		(years)		Value							Value
	Copyrights, trademarks and other registrations	19		$	99,100			$	(64,084	)	$	99,100	$	(60,119	)
	Other	19		12,600				(8,148		)	12,600		(7,644		)
				$	111,700			$	(72,232	)	$	111,700	$	(67,763	)
Schedule of Aggregate Estimated Amortization Expense	'
	The aggregate estimated amortization expense for intangible assets remaining as of September 30, 2013 is as follows:
	Remainder of 2013	$	1,488
	2014	5,957
	2015	5,957
	2016	5,957
	2017	5,957
	Thereafter	14,152
		$	39,468

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2013
Accrued Liabilities [Abstract]	'
Schedule of Accrued Liabilities	'
	Accrued liabilities consist of the following:
		September 30, 2013		December 31, 2012
	Distributor commissions	$	556,508	$	443,707
	Salaries and wages	535,042		499,894
	Sales and property taxes	102,120		69,483
	Medical products sales rebates	73,221		52,611
	Interest	9,038		9,981
	Other	16,707		35,455
		$	1,292,636	$	1,111,131

LongTerm_Obligations_Tables

Long-Term Obligations (Tables)	9 Months Ended
	Sep. 30, 2013
Long Term Obligations And Credit Lines [Abstract]	'
Schedule of Long-term Obligations	'
	Long-term obligations consist of the following:
		September 30, 2013			December 31, 2012
	Mortgage note payable bearing interest at 7.75%, payable in monthly installments of $25,797 through April 2019, collateralized by land and building, and personally guaranteed by the Company’s Chairman of the Board of Directors and Chief Executive Officer	$	1,399,424		$	1,545,499
	Less – current maturities	(208,410		)	(196,678		)
		$	1,191,014		$	1,348,821

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Share-based Compensation [Abstract]	'
Schedule of Fair Value of Option Grants	'
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:
		Quarters Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
		-1		-1		-1
	Weighted average expected life (years)	—		—		—		6
	Risk-free interest rate	—	%	—	%	—	%	0.96	%
	Expected volatility	—	%	—	%	—	%	310.09	%
	Expected dividend yield	—	%	—	%	—	%	—	%
	__________________
	(1) There were no option grants during these periods.
Schedule of Stock Option Activity	'
	A summary of stock option activity for the nine months ended September 30, 2013 is as follows:
		Options		Weighted-Average Exercise Price per Share			Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
	Outstanding on December 31, 2012	86,126		$	4
	Granted	—		—
	Exercised	—		—
	Forfeited/canceled	(15,090	)	2.87
	Outstanding on September 30, 2013	71,036		$	4.19		4.2	$	—
	Exercisable on September 30, 2013	53,060		$	4.44		3.5	$	—
Schedule of Nonvested Share Activity	'
	A summary of the status of the Company's non-vested stock options as of September 30, 2013 and changes during the nine months then ended are presented below:
		Shares		Weighted-Average Grant Date Fair Value per Share
	Non-vested stock options at December 31, 2012	19,976		$	2.94
	Non-vested stock options granted	—		—
	Vested stock options	(2,000	)	2.5
	Forfeited stock options	—		—
	Non-vested stock options at September 30, 2013	17,976		2.98

Segments_and_Geographic_Area_T

Segments and Geographic Area (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Schedule of Segment Information	'
	Segment information is as follows (U.S. dollars in 000s):
		Nutritional Products			Medical Products			Consolidated
	Quarter Ended September 30, 2013
	Net sales	$	4,999		$	1,640		$	6,640
	Depreciation and amortization	132			15			147
	Operating profit (loss)	(203		)	64			(139		)
	Capital expenditures	—			—			—
	Total assets	15,683			3,157			18,840
	Quarter Ended September 30, 2012
	Net sales	$	5,301		$	1,412		$	6,713
	Depreciation and amortization	127			19			146
	Operating loss	(453		)	(83		)	(536		)
	Capital expenditures	100			—			100
	Total assets	14,901			2,829			17,730
	Nine Months Ended September 30, 2013
	Net sales	$	14,431		$	4,594		$	19,025
	Depreciation and amortization	395			46			442
	Operating profit (loss)	(360		)	47			(313		)
	Capital expenditures	11			—			11
	Total assets	15,683			3,157			18,840
	Nine Months Ended September 30, 2012
	Net sales	$	14,652		$	4,678		$	19,330
	Depreciation and amortization	370			59			429
	Operating profit (loss)	(210		)	112			(98		)
	Capital expenditures	805			—			805
	Total assets	14,901			2,829			17,730
Summary of Financial Information by Geographic Segment	'
	Financial information summarized geographically is as follows (U.S. dollars in 000s):
		Quarter Ended September 30, 2013						Quarter Ended September 30, 2012
		Net sales			Long-Lived assets			Net sales			Long-Lived assets
	Domestic	$	2,455		$	5,859		$	2,422		$	6,442
	Russia/Eastern Europe	3,078			—			3,333			—
	Canada	374			528			339			521
	Southeast Asia	707			258			566			60
	All others	25			—			54			—
	Totals	$	6,640		$	6,645		$	6,713		$	7,023
		Nine Months Ended September 30, 2013						Nine Months Ended September 30, 2012
		Net sales			Long-Lived assets			Net sales			Long-Lived assets
	Domestic	$	7,129		$	5,859		$	7,969		$	6,442
	Russia/Eastern Europe	8,856			—			8,717			—
	Canada	1,184			528			1,072			521
	Southeast Asia	1,747			258			1,305			60
	All others	110			—			267			—
	Totals	$	19,025		$	6,645		$	19,330		$	7,023

Earnings_Loss_Per_Share_Tables

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Schedule of Basic and Diluted Earnings (Loss) Per Common Share	'
	Summarized basic and diluted loss per common share was calculated as follows:
		Net Loss			Weighted	Per Share
					Average
					Shares
	Quarter Ended September 30, 2013
	Basic loss per common share	$	(142,971	)	2,217,044	$	(0.06	)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(142,971	)	2,217,044	$	(0.06	)
	Quarter Ended September 30, 2012
	Basic loss per common share	$	(329,004	)	2,222,883	$	(0.15	)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(329,004	)	2,222,883	$	(0.15	)
	Nine Months Ended September 30, 2013
	Basic loss per common share	$	(297,951	)	2,220,916	$	(0.13	)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(297,951	)	2,220,916	$	(0.13	)
	Nine Months Ended September 30, 2012
	Basic loss per common share	$	(82,128	)	2,222,883	$	(0.04	)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(82,128	)	2,222,883	$	(0.04	)

Unaudited_Condensed_Consolidat2

Unaudited Condensed Consolidated Financial Statements Unaudited Condensed Consolidated Financial Statements (Details) (USD $)	Sep. 30, 2013	Aug. 09, 2013	Dec. 31, 2012	Aug. 09, 2013	Aug. 09, 2013
				Reverse Stock Split [Member]	Forward Stock Split [Member]
Stock Splits [Line Items]	'	'	'	'	'
Stockholders' Equity Note, Stock Split, Conversion Ratio	'	'	'	500	50
Common stock par value (in dollars per share)	$0.00	$0.00	$0.00	'	'
Share Price	'	'	'	$0.17	'

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Inventories [Abstract]	'	'
Raw materials and bulk products	$266,580	$176,872
Packaging materials	293,085	364,258
Finished goods	4,398,424	4,543,770
Inventories	$4,958,089	$5,084,900

Prepaid_Expenses_and_Other_Cur2

Prepaid Expenses and Other Current Assets (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Jul. 31, 2013	Sep. 30, 2013
			Southeast Asia [Member]	Southeast Asia [Member]	Prepaid Expense [Member]
Prepaid Expenses and Other Current Assets [Line Items]	'	'	'	'	'
Advance payment to suppliers	$417,980	$223,267	'	'	'
Prepaid income taxes	291,384	303,983	'	'	'
Advances to Associates	145,108	0	527,000	403,000	'
Marketing fees earned from associate	'	'	34,000	'	'
Advances to associates, fully reserved	'	'	115,000	'	'
Certificates of deposit - restricted	82,654	85,357	'	'	'
Prepaid insurance and other	508,813	220,851	'	'	'
Prepaid expenses and other current assets	1,445,939	833,458	'	'	'
Net advance to affiliates	$381,000	'	$493,000	'	$145,000

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Depreciation expense	$145,800	$144,300	$437,100	$424,200	'
Property and equipment, net	4,059,804	'	4,059,804	'	4,488,374
Building and Improvements [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	3,834,193	'	3,834,193	'	3,812,692
Computer Software and Office Equipment [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	2,440,309	'	2,440,309	'	2,444,383
Warehouse Equipment [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	234,625	'	234,625	'	234,625
Automotive Equipment [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	14,717	'	14,717	'	14,717
Depreciable Assets [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	6,523,844	'	6,523,844	'	6,506,417
Less: accumulated depreciation	-3,605,213	'	-3,605,213	'	-3,159,216
Property and equipment, net	2,918,631	'	2,918,631	'	3,347,201
Land [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, net	$1,141,173	'	$1,141,173	'	$1,141,173

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Summary of Goodwill Balances) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Goodwill [Roll Forward]	'
Gross Carrying Value, Beginning Balance	$3,435,305
Gross Carrying Value, Currency translation adjustment	-33,458
Gross Carrying Value, Ending Balance	3,401,847
Accumulated Amortization, Beginning Balance	-1,137,285
Accumulated Amortization, Currency translation adjustment	16,312
Accumulated Amortization, Ending Balance	($1,120,973)

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets (Summary of Other Intangible Assets) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Amortization expense	($1,500)	($1,500)	($4,500)	($4,500)	'
Gross Carrying Value	111,700	'	111,700	'	111,700
Accumulated Amortization	-72,232	'	-72,232	'	-67,763
Copyrights, trademarks and other registrations [Member]	'	'	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Average Life	'	'	'19 years	'	'
Gross Carrying Value	99,100	'	99,100	'	99,100
Accumulated Amortization	-64,084	'	-64,084	'	-60,119
Other [Member]	'	'	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Average Life	'	'	'19 years	'	'
Gross Carrying Value	12,600	'	12,600	'	12,600
Accumulated Amortization	($8,148)	'	($8,148)	'	($7,644)

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets (Aggregate Estimated Amortization) (Details) (USD $)	Sep. 30, 2013
Goodwill and Other Intangible Assets [Abstract]	'
Remainder of 2013	$1,488
2014	5,957
2015	5,957
2016	5,957
2017	5,957
Thereafter	14,152
Aggregate estimated amortization expense	$39,468

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Accrued Liabilities [Abstract]	'	'
Distributor Commissions, Current	$556,508	$443,707
Salaries and wages	535,042	499,894
Sales and property taxes	102,120	69,483
Medical product sales rebates	73,221	52,611
Interest	9,038	9,981
Other	16,707	35,455
Accrued liabilities	$1,292,636	$1,111,131

LongTerm_Obligations_Details

Long-Term Obligations (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Debt Instrument [Line Items]	'	'
Mortgage note payable bearing interest at 7.75%, payable in monthly installments of $25,797 through April 2019, collateralized by land and building, and personally guaranteed by the Companybs Chairman of the Board and Chief Executive Officer	$1,399,424	$1,545,499
Less - current maturities	-208,410	-196,678
Long-term obligations, less current maturities	1,191,014	1,348,821
Fair value of fixed-rate long-term debt	1,518,000	1,713,000
Fair value in excess of carrying value	119,000	168,000
Long-term Debt	1,399,000	1,545,000
Mortgage Note Payable [Member]	'	'
Debt Instrument [Line Items]	'	'
Interest rate (as a percentage)	7.75%	7.75%
Monthly installment payments	$25,797	$25,797

ShareBased_Compensation_Summar

Share-Based Compensation (Summary of Fair Value of Option Grants) (Details) (USD $)	3 Months Ended			9 Months Ended
	Sep. 30, 2013		Sep. 30, 2012	Sep. 30, 2013		Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'	'		'
Share-based compensation expense	$4,800		$10,400	$14,300		$28,100
Stock Options [Member]	'		'	'		'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'	'		'
Weighted average expected life	'0 years		'0 years	'0 years		'6 years
Risk-free interest rate	0.00%	[1]	0.00%	0.00%	[1]	0.96%
Expected volatility	0.00%	[1]	0.00%	0.00%	[1]	310.09%
Expected dividend yield	0.00%	[1]	0.00%	0.00%	[1]	0.00%
[1]	There were no option grants during these periods.

ShareBased_Compensation_Summar1

Share-Based Compensation (Summary of Stock Option Activity) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Options, Outstanding [Roll Forward]	'
Options, Beginning Balance Outstanding	86,126
Options, Granted	0
Options, Exercised	0
Options, Forfeited/canceled	-15,090
Options, Ending Balance Outstanding	71,036
Options, Exercisable	53,060
Outstanding, Weighted-Average Exercise Price per Share [Roll Forward]	'
Weighted-Average Exercise Price per Share, Beginning Balance Outstanding	$4
Weighted-Average Exercise Price per Share, Granted	$0
Weighted-Average Exercise Price per Share, Exercised	$0
Weighted-Average Exercise Price per Share, Forfeited/canceled	$2.87
Weighted-Average Exercise Price per Share, Ending Balance Outstanding	$4.18
Weighted-Average Exercise Price per Share, Exercisable	$4.44
Weighted-Average Remaining Contractual Term, Outstanding	'4 years 2 months 13 days
Weighted-Average Remaining Contractual Term, Exercisable	'3 years 5 months 25 days
Aggregate Intrinsic Value, Outstanding	$0
Aggregate Intrinsic Value, Exercisable	$0

ShareBased_Compensation_Summar2

Share-Based Compensation (Summary of Non-vested Stock Options) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Non-vested Stock Options, Number of Shares [Roll Forward]	'
Shares, Non-vested stock options, Beginning Balance	19,976
Shares, Non-vested stock options granted	0
Shares, Vested stock options	-2,000
Shares, Forfeited stock options	0
Shares, Non-vested stock options, Ending Balance	17,976
Non-vested Stock Options, Weighted Average Grant Date Fair Value [Roll Forward]	'
Weighted Average Grant Date Fair Value per Share, Non-vested stock options, Beginning Balance	$2.94
Weighted Average Grant Date Fair Value per Share, Non-vested stock options granted	$0
Weighted Average Grant Date Fair Value per Share, Vested stock options	$2.50
Weighted Average Grant Date Fair Value per Share, Forfeited stock options	$0
Weighted Average Grant Date Fair Value per Share, Non-vested stock options, Ending Balance	$2.98
Total unrecognized compensation cost related to stock option grants	$41,200

Segments_and_Geographic_Area_S

Segments and Geographic Area (Summary of Segment Information) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
			segment
Segment Reporting Information [Line Items]	'	'	'	'	'
Number of Operating Segments	'	'	2	'	'
Net sales	$6,639,767	$6,713,068	$19,025,267	$19,330,438	'
Depreciation and amortization	147,000	146,000	441,593	428,710	'
Operating profit (loss)	-138,520	-535,880	-312,952	-97,605	'
Purchase of property and equipment	0	100,000	11,292	805,131	'
Total assets	18,839,656	17,730,000	18,839,656	17,730,000	18,014,421
Nutritional Products [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	4,999,000	5,301,000	14,431,000	14,652,000	'
Depreciation and amortization	132,000	127,000	395,000	370,000	'
Operating profit (loss)	-203,000	-453,000	-360,000	-210,000	'
Purchase of property and equipment	0	100,000	11,000	805,000	'
Total assets	15,683,000	14,901,000	15,683,000	14,901,000	'
Medical Products [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	1,640,000	1,412,000	4,594,000	4,678,000	'
Depreciation and amortization	15,000	19,000	46,000	59,000	'
Operating profit (loss)	64,000	-83,000	47,000	112,000	'
Purchase of property and equipment	0	0	0	0	'
Total assets	$3,157,000	$2,829,000	$3,157,000	$2,829,000	'
Minimum [Member] | Nutritional Products [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Number of products	'	'	100	'	'
Minimum [Member] | Medical Products [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Number of products	'	'	40	'	'

Segments_and_Geographic_Area_S1

Segments and Geographic Area (Summary of Financial Information by Geographic Location) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	$6,639,767	$6,713,068	$19,025,267	$19,330,438
Long-Lived assets	6,645,000	7,023,000	6,645,000	7,023,000
Domestic [Memeber]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	2,455,000	2,422,000	7,129,000	7,969,000
Long-Lived assets	5,859,000	6,442,000	5,859,000	6,442,000
Russia/Eastern Europe [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	3,078,000	3,333,000	8,856,000	8,717,000
Long-Lived assets	0	0	0	0
Canada [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	374,000	339,000	1,184,000	1,072,000
Long-Lived assets	528,000	521,000	528,000	521,000
Southeast Asia [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	707,000	566,000	1,747,000	1,305,000
Long-Lived assets	258,000	60,000	258,000	60,000
All others [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	25,000	54,000	110,000	267,000
Long-Lived assets	$0	$0	$0	$0

Segments_and_Geographic_Area_S2

Segments and Geographic Area (Summary Significant Customers) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	$6,639,767	$6,713,068	$19,025,267	$19,330,438
Nutritional Products [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	4,999,000	5,301,000	14,431,000	14,652,000
Medical Products [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	1,640,000	1,412,000	4,594,000	4,678,000
Coral Club International, Inc. [Member] | Nutritional Products [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	3,078,000	3,333,000	8,856,000	8,717,000
Medical/Surgical Dealer [Member] | Medical Products [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	$672,000	$612,000	$1,960,000	$2,512,000
President of Related Entity and Former Director [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Equity Method Investment, Ownership Percentage	18.00%	'	18.00%	'

Earnings_Loss_Per_Share_Detail

Earnings (Loss) Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]	'	'	'	'
Net Earnings (Loss), Basic	($142,971)	($329,004)	($297,951)	($82,128)
Net Earnings (Loss), Diluted	($142,971)	($329,004)	($297,951)	($82,128)
Weighted Average Shares, Basic	2,217,044	2,222,883	2,220,916	2,222,883
Weighted Average Shares, Effect of dilutive stock options	0	0	0	0
Weighted Average Shares, Diluted	2,217,044	2,222,883	2,220,916	2,222,883
Earnings per share, basic (usd per share)	($0.06)	($0.15)	($0.13)	($0.04)
Earnings per share, diluted (usd per share)	($0.06)	($0.15)	($0.13)	($0.04)
Antidilutive stock options excluded from earnings per share calculation	71,000	107,400	76,000	103,000

Legal_Proceedings_Details

Legal Proceedings (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Loss Contingencies [Line Items]	'	'	'	'
Net sales	$6,639,767	$6,713,068	$19,025,267	$19,330,438
Concentration Rrisk (percent)	'	'	10.00%	13.00%
Percentage of revenue (percent)	90.00%	'	'	'
Medical Products [Member]	'	'	'	'
Loss Contingencies [Line Items]	'	'	'	'
Net sales	1,640,000	1,412,000	4,594,000	4,678,000
Medical/Surgical Dealer [Member] | Medical Products [Member]	'	'	'	'
Loss Contingencies [Line Items]	'	'	'	'
Net sales	672,000	612,000	1,960,000	2,512,000
Subsequent Event [Member]	'	'	'	'
Loss Contingencies [Line Items]	'	'	'	'
Accounts Receivable, From Major Customer in Bankruptcy Court, Pre-Petition	$240,000	'	$240,000	'